Status:
ACTIVE_NOT_RECRUITING
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Esophageal Squamous Cell Carcinoma (ESCC)
Cervical Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study is a multicenter cohort investigation integrating both retrospective and prospective components, designed to evaluate the predictive performance of combined blood ELISA testing and tissue m...
Detailed Description
1. Study Title Biomarkers for Predicting Response to PD-1 Inhibitor Therapy in Squamous Cell Carcinoma: A Retrospective-Prospective Cohort Study 2. Background and Rationale Squamous Cell Carcinoma (SC...
Eligibility Criteria
Inclusion
- Patients with pathologically confirmed esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), or lung squamous cell carcinoma (LSCC), regardless of surgical eligibility
- For surgically eligible patients: Planned to receive neoadjuvant PD-1 inhibitor ± chemotherapy as first-line treatment
- For surgically ineligible patients: Planned to receive PD-1 inhibitor ± chemotherapy as first-line treatment
- Availability of pre-treatment biopsy tissue and baseline blood samples
- Capable of providing informed consent
Exclusion
- Patients with concurrent other types of malignancies
- Patients who have already undergone prior antitumor therapy
Key Trial Info
Start Date :
April 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT07147361
Start Date
April 28 2022
End Date
July 31 2027
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Etiology and Carcinogenesis
Beijing, Beijing Municipality, China, 100021